Biomarkers to Improve Decision-making in Acute Heart Failure
暂无分享,去创建一个
[1] A. Cohen-Solal,et al. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology , 2022, European journal of heart failure.
[2] A. Bayés‐Genís,et al. Assessment of filling pressures and fluid overload in heart failure: an updated perspective. , 2022, Revista espanola de cardiologia.
[3] P. Lourenço,et al. CA‐125 variation in acute heart failure: a single‐centre analysis , 2022, ESC heart failure.
[4] Natasha Meunier-McVey,et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure , 2021, EMJ Cardiology.
[5] A. Mebazaa,et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC) , 2021, European journal of heart failure.
[6] A. Bayés‐Genís,et al. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. , 2021, European journal of internal medicine.
[7] W. Mullens,et al. Cardiac congestion assessed by natriuretic peptides oversimplifies the definition and treatment of heart failure , 2021, ESC heart failure.
[8] J. Lupón,et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review , 2021, European journal of heart failure.
[9] P. Ponikowski,et al. Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge , 2021, ESC heart failure.
[10] J. Struck,et al. Bioactive adrenomedullin in plasma is associated with biventricular filling pressures in patients with advanced heart failure , 2020, European journal of heart failure.
[11] A. Bayés‐Genís,et al. CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. , 2020, International journal of cardiology.
[12] A. Bayés‐Genís,et al. Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure , 2020, European heart journal. Acute cardiovascular care.
[13] M. Metra,et al. Clinical Role of CA125 in Worsening Heart Failure: A BIOSTAT-CHF Study Subanalysis. , 2020, JACC. Heart failure.
[14] G. Filippatos,et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations , 2019, European journal of heart failure.
[15] N. Samani,et al. Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure , 2019, European journal of heart failure.
[16] G. Filippatos,et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.
[17] A. Mebazaa,et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application , 2018, European journal of heart failure.
[18] J. Januzzi,et al. Established and Emerging Roles of Biomarkers in Heart Failure , 2018, Circulation research.
[19] A. Voors,et al. Bio‐adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure , 2018, European journal of heart failure.
[20] Akshay S. Desai,et al. Spot Urine Sodium as Triage for Effective Diuretic Infusion in an Ambulatory Heart Failure Unit. , 2018, Journal of cardiac failure.
[21] W. Peacock,et al. N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study. , 2018, Journal of the American College of Cardiology.
[22] G. Fonarow,et al. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure , 2017, European heart journal. Acute cardiovascular care.
[23] J. Lupón,et al. Original InvestigationEditorial CommentSoluble ST2 for Prognosis and Monitoring in Heart Failure: The New Gold Standard?∗ , 2017 .
[24] Y. Pinto,et al. Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. , 2017, Journal of the American College of Cardiology.
[25] A. Mebazaa,et al. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. , 2017, JACC. Heart failure.
[26] M. Emdin,et al. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. , 2017, JACC. Heart failure.
[27] S. Morell,et al. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study. , 2016, JACC. Heart failure.
[28] P. Ponikowski,et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX‐AHF study , 2015, European journal of heart failure.
[29] Adrian F. Hernandez,et al. Transitions of care in heart failure: a scientific statement from the American Heart Association. , 2015, Circulation. Heart failure.
[30] Y. Pinto,et al. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study. , 2014, Journal of cardiac failure.
[31] W. Tang,et al. Urinary Composition During Decongestive Treatment in Heart Failure With Reduced Ejection Fraction , 2014, Circulation. Heart failure.
[32] W. Tang,et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. , 2014, Journal of cardiac failure.
[33] Y. Pinto,et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ÉLAN-HF Score , 2013, Heart.
[34] C. Parikh,et al. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. , 2013, Journal of the American College of Cardiology.
[35] V. Hasselblad,et al. Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study , 2012, European journal of heart failure.
[36] G. Fonarow,et al. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. , 2012, International journal of cardiology.
[37] J. Alpert,et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. , 2012, European heart journal.
[38] Carlo Lombardi,et al. Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure: Analysis From the PROTECT Pilot Study , 2011, Circulation. Heart failure.
[39] Eric M. Reyes,et al. Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes: Data From Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Linked to Medicare Claims , 2011, Circulation. Heart failure.
[40] C. Frampton,et al. Regional clearance of amino‐terminal pro‐brain natriuretic peptide from human plasma , 2009, European journal of heart failure.
[41] R. Fitzgerald,et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. , 2008, Journal of cardiac failure.
[42] G. Fonarow,et al. Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.
[43] C. Phillips,et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.
[44] J. Burnett,et al. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. , 2005, Mayo Clinic proceedings.
[45] E. Frohlich,et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. , 2004, Journal of the American College of Cardiology.
[46] D. Levy,et al. Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.
[47] P. Krishnaswamy,et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. , 2001, Journal of cardiac failure.
[48] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[49] V. Hombach,et al. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end‐diastolic pressure , 1993, Clinical cardiology.
[50] OUP accepted manuscript , 2021, European Heart Journal.
[51] E. Núñez,et al. [Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission]. , 2012, Medicina clinica.
[52] A. Bayés‐Genís,et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. , 2010, Revista espanola de cardiologia.
[53] Cardiac Failure Review , 2022 .
[54] Soluble ST2 for Prognosis and Monitoring in Heart Failure The , 2022 .